Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells
Since many oncogenes, including <i>BCR-ABL</i>, may promote the acquisition and maintenance of the glycolytic phenotype, we tested whether treatment of BCR-ABL-driven human leukemia cells with imatinib, a selective BCR-ABL inhibitor, can modulate the expression of key glycolytic enzymes...
Main Authors: | Viviana De Rosa, Marcello Monti, Cristina Terlizzi, Rosa Fonti, Silvana Del Vecchio, Francesca Iommelli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/13/3134 |
Similar Items
-
Transcripto BCR-ABL atípico en un paciente con leucemia mieloide crónica Atypical BCR-ABL transcript in a patient with chronic myeloid leukemia
by: Ana María Amor Vigil, et al.
Published: (2011-09-01) -
A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
by: Liuya Wei, et al.
Published: (2020-09-01) -
A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells
by: Patricia Martín-Rodríguez, et al.
Published: (2019-01-01) -
Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
by: Mousa Vatanmakanian, et al.
Published: (2019-04-01) -
Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis
by: Poonam P Jain, et al.
Published: (2012-01-01)